Adma Biologics (ADMA) Gains from Sales and Divestitures (2020 - 2025)

Adma Biologics has reported Gains from Sales and Divestitures for 6 years, with the latest figure at $1.9 million in Q4 2025.

• For the quarter ending Q4 2025, Gains from Sales and Divestitures fell 0.61% year-over-year to $1.9 million; the trailing twelve-month figure through Dec 2025 stood at $1.9 million (down 0.61% YoY), and the FY2025 full-year result was $1.9 million, down 0.61% from the prior year.
• Gains from Sales and Divestitures for Q4 2025 stood at $1.9 million, up from $1.8 million in the prior quarter.
• The five-year high for Gains from Sales and Divestitures was $2.7 million in Q4 2022, with the low at $87750.0 in Q2 2021.
• Historically, Gains from Sales and Divestitures has averaged $1.1 million across 5 years, with a median of $1.2 million in 2023.
• Annual changes were most pronounced in 2022 — Gains from Sales and Divestitures jumped 2840.61% — and 2023, when it tumbled 56.02%.
• Adma Biologics' Gains from Sales and Divestitures stood at $92750.0 in 2021, then jumped by 2840.61% to $2.7 million in 2022, then plunged by 56.02% to $1.2 million in 2023, then jumped by 57.28% to $1.9 million in 2024, then slipped by 0.61% to $1.9 million in 2025.
• The last three Gains from Sales and Divestitures figures came in at $1.9 million (Q4 2025), $1.8 million (Q3 2025), and $1.6 million (Q2 2025), per Business Quant data.